Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is ...

The FDA has outlined numerous concerns about the sale and use of unapproved GLP-1 drugs for weight loss.  “FDA is aware that ...

Hims is breaching the U.S. patent on semaglutide, the active ingredient in Novo’s Wegovy obesity treatments, Novo argued ...

FDA enforcement will focus on restricting GLP-1 APIs in mass-marketed, nonapproved compounded products to address unverifiable quality, safety, and efficacy under the FD&C Act. Appropriate compounding ...

Hims & Hers Health shares plunged Monday after the telehealth company said it would stop selling its compounded weight-loss ...

By Leah Douglas and Siddhi Mahatole Feb 6 (Reuters) - The U.S. Food and Drug Administration said on Friday it would take ...

Novo Nordisk is suing US telehealth company Hims & Hers to stop it selling “knock-off” versions of its weight-loss drugs, as Hims’ shares sank more than 20 per cent after regulators announced an ...

Semaglutide is the active ingredient in Ozempic and Wegovy. It’s a synthetic form of GLP-1, a hormone that regulates our appetite and hunger. The trouble between Hims and Novo Nordisk over its ...

Hims & Hers said it would stop selling its new compounded semaglutide pill after "constructive conversations with ...

Hims & Hers (NYSE:HIMS) shares are plunging 16% in after-hours trading following coordinated moves by two federal agencies ...

Novo's lawsuit comes less than one week after Hims & Hers announced plans to sell a compounded version of Novo's weight-loss ...

Feb 6 (Reuters) - The U.S. Food and Drug Administration said on Friday it plans to restrict GLP-1 ingredients used in ...